179 results on '"Castella, Barbara"'
Search Results
2. Preclinical efficacy of carfilzomib in BRAF‐mutant colorectal cancer models
3. MM-324 Effects of Soluble and Microvesicle-Bound Therapeutic Anti-CD38 Antibodies on Immune Effector Cells in Multiple Myeloma
4. Supplementary Figures from Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors
5. Data from Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors
6. Supplementary Materials and Methods from Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors
7. Supplementary Figure Legends from Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors
8. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer
9. Immune dysfunctions affecting bone marrow Vγ9Vδ2 T cells in multiple myeloma: Role of immune checkpoints and disease status
10. Additional file 1 of Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity
11. Poster: MM-324 Effects of Soluble and Microvesicle-Bound Therapeutic Anti-CD38 Antibodies on Immune Effector Cells in Multiple Myeloma
12. Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells
13. Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus Acute Lymphoblastic Leukemia study
14. Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study
15. Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside
16. Molecular dynamics of targeting CD38 in multiple myeloma
17. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid
18. Immunomodulatory and clinical effects of daratumumab in T‐cell acute lymphoblastic leukaemia
19. Mitochondrial metabolism: Inducer or therapeutic target in tumor immune-resistance?
20. Novel anthracyclines with enhanced immunogenic effects against drug resistant osteosarcoma cells
21. Additional file 4: of Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer
22. Additional file 2: of Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer
23. Additional file 1: of Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer
24. Additional file 11: of Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer
25. Additional file 7: of Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer
26. Additional file 9: of Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer
27. Additional file 6: of Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer
28. Additional file 8: of Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer
29. Additional file 5: of Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer
30. Additional file 3: of Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer
31. CyTOF®: A New Tool to Decipher the Immunomodulatory Activity of Daratumumab
32. Ectonucleotidase Expression on Human Amnion Epithelial Cells: Adenosinergic Pathways and Dichotomic Effects on Immune Effector Cell Populations
33. Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma
34. Abstract 2122: Induction of structural and functional effects of myeloma cells after daratumumab treatment
35. Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression
36. ABCA1, apoA-I, and BTN3A1: A Legitimate Ménage à Trois in Dendritic Cells
37. The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells
38. CD38 and Antibody Therapy: What Can Basic Science Add?
39. ATP-Binding-Cassette A1 Regulates Extracellular Isopentenyl Pyrophosphate Release and Vγ9Vδ2 T-Cell Activation By Dendritic Cells
40. Immune Checkpoint Blockade Combinations As Promising Strategy for Cancer Immunotherapy in Multiple Myeloma Patients
41. Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia
42. Mechanisms of Vgamma9Vdelta2 T cell activation by soluble metabolites generated by the mevalonate pathway
43. Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia
44. The association of dexamethasone + simvastatin to overcome environment-mediated chemoresistance of chronic lymphocytic leukemia (CLL) cells
45. IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY IMMUNE RESPONSES ELICITED BY SELF ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA
46. Role of PD-1/PD-L1 axis in the immune paresis of bone marrow Vγ9Vδ2 T cells in multiple myeloma
47. The CXCR4 Downstream Signaling Pathways in Chronic Lymphocytic Leukemia: a Target to Reverse Microenvironment Protection
48. Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors
49. Serological Proteome Analysis (SERPA) as a tool for the identification of novel tumor antigens in chronic lymphocytic leukemia (CLL)
50. SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.